Test in Focus
T-cell lymphoma is a term used to describe a group of cancers derived from T cells, which are cells of the immune system that play a critical role in immune function. T-cell lymphoma is not a single disease, but rather a name given to a wide variety of diseases that have different pathologic and clinical features.
With more than 30 identified subtypes of T-cell lymphoma in existence, making an accurate, definitive diagnosis can be difficult. In addition to an extensive IHC and FISH test offerings, Mayo Clinic’s hematopathology team not only has extensive experience detecting and diagnosing T-cell neoplasms, but also frequently provides T-cell lymphoma consultations for clients around the globe to help give clinicians the diagnostic answers they need to effectively treat T-cell lymphoma patients.
“The most common molecular assays that we do right now are T-cell receptor gene rearrangement studies for clonality,” says clinical hematopathologist Andrew Feldman, M.D. “And that's often used to differentiate between clonal or neoplastic processes and reactive processes.”
Learn more by listening to the below “Test in Focus” episode of our “Answers From the Lab” podcast with Dr. Feldman.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebral spinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.